The role of tumor necrosis factor in allograft rejection: III. Evidence that anti-tnf antibody therapy prolongs allograft survival in rats with acute rejection

Transplantation

Volumn 51, Issue 1, 1991, Pages 57-62

  Imagawa, David K ^a,b   Millis, J Michael ^a   Seu, Philip ^a   Olthoff, Kim M ^a   Hart, John ^a   Wasef, Evette ^a   Dempsey, Roy A ^c   Stephens, Sue ^d   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Endogen Corporation ^*  (United States)

^d Celltech Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LIVER TRANSPLANTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMAL; ANTIBODIES; CYCLOSPORINS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MALE; RATS; RATS, INBRED BUF; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR;

EID: 0026080583     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199101000-00008     Document Type: Article

References (41)

1. Moore RN, Oppenheim JJ, Farrar JJ, et al. Production of lymphocyte-activating factor (interleukin 1) by macrophages activated with colony stimulating factors. J Immunol 1980; 125: 1302.
2. Kaye JS, Gillis S, Mizel SB, et al. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol 1984; 133: 1339.
3. Cantrell DA, Smith KA. Transient expression of interleukin-2 receptors: consequences for T cell growth. J Exp Med 1983; 158: 1895.
4. Pace JL, Russell SW, Schreiber RD, Altman A, Katz DH. Macro phage activation: priming activity from a T-cell hybridoma is attributable to gamma-interferon. Proc Natl Acad Sci USA 1983; 80: 3782.
5. Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin Amediates immunosuppression of primary cytotoxic T cell re-sponses by impairing the release of interleukin-1 and interleukin- 2. Eur J Immunol 1981; 11:657.
6. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppres sant FK506 selectively inhibits expression of early T cell acti-vation genes. J Immunol 1989; 143: 718.
7. Snyder DS, Unanue ER. Corticosteroids inhibit murine macro phage la expression and interleukin-1 production. J Immunol 1982; 129: 1803.
8. Caine RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 1961; 26: 65.
9. Monaco AP. Antilymphocyte globulin: a clinical transplantation research opportunity. Am J Kidney Dis 1982; 2: 67.
10. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplan-tation 1981; 32: 535.
11. Cornaby A, Simpson MA, VannRice R, et al. Interleukin-2 levels and urine cytology distinguish between cyclosporine toxicity and rejection in renal and liver allograft recipients. Transplant Proc 1988; 20: (suppl 3): 827.
12. Adams DH, Wang L, Hubscher SG, Elias E, Neuberger JM. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1989; 8636: 469.
13. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RAF. Soluble interleukin-2 receptor level as an indicator of liver allo-graft rejection. Transplantation 1989; 47: 77.
14. Tellides G, Dallman MJ, Kupiec-Weglinski JW, Diamantstein T, Morris PJ. Functional blocking of the interleukin-2 receptor (IL- 2R) may be important in the efficacy of IL-2R antibody therapy. Transplant Proc 1987; 19: 4231.
15. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624.
16. Cantarovich D, Le Mauff B, Hourmant M, et al. Prophylactic use of a monoclonal antibody (33B 3.1) directed against interleukin 2 receptor following human renal transplantation. Am J Kidney Dis 1988; 11: 101.
17. Kirkman RL, Shapiro ME, Carpenter CB, et al. Early experience with anti-Tac in clinical renal transplants. Transplant Proc 1989; 21: 1766.
18. Soulillou J-P, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin- 2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
19. Moy J, Rosenau W. Demonstration of a-lymphotoxin in human rejected renal allografts. Clin Immunol Immunopathol 1981; 20: 49.
20. Lowry RP, Blais D. Tumor necrosis factor-alpha in rejecting rat cardiac allografts. Transplant Proc 1988; 20: 245.
21. Maury CPJ, Teppo AM. Raised serum levels of cachectin/tumornecrosis factor-a in renal allograft rejection. J Exp Med 1987; 166: 1132.
22. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumornecrosis factor in allograft transplantation: I. Elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990; 50: 219.
23. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumornecrosis factor-a precede major complications of bone marrow transplantation. Blood 1990; 1011.
24. Abramowicz D, Schandene L, Goldman M, et al. Release of tumornecrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
25. Piguet P-F, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280.
26. Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 1989; 47: 1057.
27. Imagawa DK, Millis JM, Olthoff KM, et al. Anti-tumor necrosis factor antibody enhances allograft survival in rats. J Surg Res 1990; 48: 345.
28. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumornecrosis factor in allograft rejection: II. Antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189.
29. Teramoto K, Baquerizo A, Imagawa DK, Olthoff KM, Dempsey R, Busuttil RW. Prolongation of hepatic allograft survival in rat recipients treated with anti-lymphotoxin antibody. Transplant Proc (in press).
30. Ono K, Lindsey E. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
31. Sheehan KCF, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989; 142: 3884.
32. Takiff H, Novak M, Iwaki Y, Terasaki PI. Low-dose cyclosporine maintenance therapy after immunosuppressive induction in a rat cardiac transplant model. Transplantation 1988; 45: 297.
33. Tilney NL, Padberg WM, Lord RHH, Araneda D, Strom TB, Kupiec-Weglinski JW. Synergy between subtherapeutic doses of cyclosporine and immunobiological manipulations in rat heart graft recipients. Transplantation 1988; 46: 122S.
34. Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allo-transplantation in rats. Transplantation 1987; 44: 734.
35. Economou JS, McBride WH, Essner R, et al. Tumor necrosis factor production by interleukin-2 activated macrophages in vitro and in vivo. Immunology 1989; 67: 514.
36. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α- mediated enhancement of T cell responses. J Immunol 1987; 138: 1786.
37. Ranges GE, Figari IS, Espevik T, Palladino MA Jr. Inhibition of cytotoxic T cell development by transforming growth factor-beta and reversal by recombinant tumor necrosis factor-alpha. J Exp Med 1987; 166: 991.
38. Tracey KJ, Lowry SF, Cerami A. Physiological responses to cachectin. In: Bock G, Marsh J, eds. Tumor necrosis factor and related cytotoxins. New York: Wiley, 1987: 88.
39. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45.
40. Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30: 964.
41. O’Grady JG, Forbes A, Rolles K, et al. An analysis of cyclosporine efficacy and toxicity after liver transplantation. Transplantation 1988; 45: 575.